VIDEO: Belzutifan major topic in renal cell carcinoma, von Hippel-Lindau disease treatment
Click Here to Manage Email Alerts
In this video, Brad McGregor, MD, clinical director of Dana-Farber Cancer Institute's Lank Center for Genitourinary Cancer, discussed the rise of hypoxia-inducible factor-2 inhibitors to treat renal cell carcinoma.
McGregor highlighted an Italian study presented at the American Urological Association Annual Meeting that examined the use of belzutifan (Welireg, Merck) to treat renal cell carcinoma and reaffirmed its status as an important drug in treating von Hippel-Lindau disease.
“We look forward to data in the future for the use of belzutifan for patients with sporadic, metastatic renal cell carcinoma as well as ongoing studies looking at combining belzutifan with immunotherapy in the adjuvant setting,” McGregor said.
Collapse
Read more about
Click Here to Manage Email Alerts